anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide an apparatus and a method for drug delivery onto a human body surface.  <P>SOLUTION: A formulation is composed of a drug, a conversion agent for converting the formulation from a less solid phase to a coherent soft solid phase and a vehicle medium or a carrier for the drug and the conversion agent. The drug formulation in the less solid phase is applied onto the human body surface and then converted into a soft solid phase during the drug delivery through the human body surface. After completing the drug delivery, the soft solid formulation can be removed or peeled as a coherent solid formulation from the human body surface. The drug formulation can be subjected to control over the drug delivery rate and the formulation can be removed without leaving the stained formulation on the body surface. An applicator used for application onto the skin is composed of a container 12 containing the drug introduced thereinto, a nozzle 10 and a flat thin opening 16.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The present invention is directed to antibodies and fragments thereof having binding specificity for FZD7, which preferably will not substantially interact with (bind to) other FZD family members, and methods of making said anti-FZD7 antibodies and binding fragments thereof. Another embodiment of this invention relates to the antibodies and binding fragments thereof comprising the sequences of the V H , V L  and/or CDR polypeptides described herein. The invention also contemplates conjugates of anti-FZD7 antibodies and binding fragments thereof, e.g., antibody-drug conjugates, as well as chimeric antigen receptor T cells and NK cells based on the anti-FZD7 antibodies and binding fragments thereof. The invention further contemplates the use of the anti-FZD7 antibodies and binding fragments thereof for tissue engineering. Another embodiment of this invention relates to a transgenic mouse expressing the epitope of the anti-FZD7 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-FZD7 antibodies and binding fragments thereof (as well as the identified FZD7 epitope) for the diagnosis, assessment, prevention and/or treatment of diseases and disorders associated with aberrant FZD7 expression, such as cancer.
Primary amebic meningoencephalitis (PAM) is a necrotizing and hemorrhagic inflammation of the brain and meninges caused by Naegleria fowleri, a free-living thermophilic ameba of freshwater systems. PAM remains a neglected disease that disproportionately affects children in tropical and subtropical climates, with an estimated mortality rate of 95-98%. Due to anthropogenic climate change, the average temperature in the USA has increased by 0.72 to 1.06 °C in the last century, promoting the poleward spread of N. fowleri. PAM is often misdiagnosed as bacterial meningitis or viral encephalitis, which shortens the window for potentially life-saving treatment. Diagnosis relies on the patient's history of freshwater exposure and the physician's high index of suspicion, supported by cerebrospinal fluid studies. While no experimental trials have been conducted to assess the relative efficacy of treatment regimens, anti-amebic therapy with adjunctive neuroprotection is standard treatment in the USA. We performed a literature review and identified five patients from North America between 1962 and 2022 who survived PAM with various degrees of sequelae.
A method for treating posthysterectomic syndrome in the patients with neurovegetative and psychoemotional disorders comprises the substitution hormonal therapy with Femoston, psychopharmacological treatment and use of antidepressants. Femoston 1/10 is provided in cyclic regimen. Valerian 0.02 g twice a day, the tincture of the motherwort 30 drops thrice a day, Hydazepam 5 mg daily before the night sleep for 10-14 days are used as psychopharmacological components. Paroxetin (Paxil) 20 mg daily for 1-3 months is provided as antidepressant for the patients with the significant depressive component. In peripheral blood, the content of pro- and anti-inflammatory cytokines is assessed by ELISA technique. The three-fold increase in the level of proinflammatory cytokines IL-Iβ, IL-6 in with concomitant 1.3-1.4-fold decrease in the level of their antagonists IL-4, IL-10 is considered as indication for Immunomax injections at a dose of 100-200 U until normalization of cytokine profile.
The name of the present invention is a life prolonging slice for elderly people. The life prolonging slice for elderly people belongs to the technical field of nutritious health-care products. The life prolonging slice mainly uses jerusalem artichoke polysaccharides as a raw material and ginkgo biloba leaves or ginkgo biloba leaf extract, ginkgo biloba leaf solution, B6, folic acids, and B12 as accessory materials. The life prolonging slice is respectively subjected to crushing, grinding, screening, compound blending with a disintegrating agent, a binder, and a lubricant, granulating, and tabletting. The life prolonging slice can promote blood circulation and remove blood stasis, prevent and cure lung deficiency and cough and asthma, cerebral thrombosis, coronary heart disease, angina, high cholesterol, prevent against cancer, beautify feature and prolong life, and has no harm to human body and has more health care value. The life prolonging slice is mainly characterized by consisting of 50-70 parts (wt) of jerusalem artichoke polysaccharides; 10-20 parts (wt) of ginkgo biloba leaf powder or ginkgo biloba leaf extract; 40-60 parts (by volume) of ginkgo biloba leaf solution; 10-15 parts (wt) of B6; 7-10 parts (wt) of folic acids; 3-5 parts (wt) of B12; 5-7 parts (wt) of sodium carboxymethyl starch; 20-30 parts by volume fraction of binder; and 0.1-0.2% by mass fraction of magnesium stearate lubricant. The processing steps are as follows: (1) jerusalem artichoke polysaccharide extraction and purification; (2) ginkgo biloba leaf active ingredient extraction; and (3) preparation of the life prolonging slice for elderly people.
The control group receiving the standard of care (SOC), i.e. heparins/VKA regimen. Patients will receive the current recommended therapy: subcutaneous or intravenous UFH/VKA in case of severe renal insufficiency and subcutaneous LMWH/VKA in case of moderate renal insufficiency for at least 5 days. VKA will begin concomitantly and continue for 3 months.
In the shaping of keratin fibres, fibres are (a) treated with a soln. contg. a reducing agent to break the cystine bonds in the fibres, (b) rinsed, (c) treated with an oxidising agent to re-form the cystine bonds, and (d) rinsed. After step (a) the fibres are rinsed with an aq. soln. of a substance inert to the fibres, so that at no point in the rinsing is the dia. of the fibres more than 30% greater than at the end of the redn. step. At no point in the rinsing is the dia. of the fibres more than 10% greater than at the end of the redn. stage; pref., there is no increase in dia.. Rinsing causes a redn. in the max. increase in fibre dia. of at least 20% (at least 50%), w.r.t. rinsing with water. Rinsing soln. has an osmotic pressure, w.r.t. water, at 25 deg.C, of 6-380 x 10 power(5) Pa, and is an aq. NaCl soln., esp. contg. 10-350g NaCl/l. After the start of the rinsing with the soln. of inert substance, water is added (dis)continuously to reduce the concn. of the inert substance, until rinsing is with water alone, or rinsing with the soln. of the inert substance may be followed by rinsing with water. Inert substances may be physiologically acceptable Na, NH4, K, Li, Mg, or Al salts (pref.  chlorides, bromide, sulphates, acetates, citrates and/or lactates), betaine, ethanol, glycerol, and/or D-sorbitol. USE/ADVANTAGE - Fibres are human hair or wool, and the process is esp. used in permanent waving of hair, but may also be the fixing of wool flat goods, or the permanent pleating of clothing. Damage to the fibres is reduced.
PURPOSE: A microcapsule for oral administration and a method for manufacturing the same are provided to improve mucosal adhesion and durability. CONSTITUTION: A microcapsule for oral administration contains 40-85 wt% of alginate, 5-20 wt% of poly-L-lysine, 5-20 wt% of alginate with a thiol group, and 5-20 wt% of physiologically active substance. The alginate is denoted by chemical formula 1. A method for preparing the alginate with the thiol group comprises: a step of adding L-cysteine salt to a reaction mixture; a step of adjusting pH of reacted mixture; and a step of performing dialysis of the reaction mixture. The average particle diameter of the microcapsule is 5-5000 um. A method for preparing the microcapsule comprises: a step of suspending the physiologically active substance in saline solution and adding alginate to the suspension; a step of reacting the reaction mixture in a calcium salt solution; a step of reacting the reaction mixture in a poly-L-lysine solution; and a step of coating the reaction mixture with the alginate solution containing thiol groups.
The present invention provides a method of enhancing immunity in a mammal. The method comprises modifying a dendritic cell (DC) in vivo or ex vivo to produce a dendritic cell-mediator in the mammal. The dendritic cell-mediator up-regulates DC in the mammal, thereby enhancing immunity in the mammal. The present invention further provides a method of inducing an immune response to an antigen, cancer, or infectious disease in a mammal. In one embodiment, the method comprises administering the antigen or an antigen of the cancer or infectious disease to a mammal, which has been treated as described above, whereupon an immune response to the antigen, cancer, or infectious disease, respectively, is induced in the mammal. In another embodiment, the method comprises administering a DC to a mammal as described above, however, the method further comprises contacting the DC, which has been modified to produce a dendritic cell-mediator, with the antigen or an antigen of the cancer or infectious disease prior to administration of the DC to the mammal, whereupon an immune response to the antigen, cancer or infectious disease, respectively, is induced in the mammal.
Aging is associated with a progressive development of impaired glucose tolerance (IGT), due to an increased peripheral tissue resistance to the action of insulin. Insulin resistance, a common state in both obese and sedentary individuals, eventually leads to the development of glucose intolerance, and type 2 diabetes with aging. Even in the absence of diabetes, insulin resistance is a key feature in various metabolic abnormalities that increase the risk for developing cardiovascular disease (CVD). Previous studies demonstrate improvements in glucose tolerance and glucose utilization following moderate energy restriction coupled with moderate intensity AEX. WL, through behavioral modification of diet and aerobic exercise (AEX), is perhaps the most effective way to treat as well as prevent insulin resistance and its associated metabolic complications of IGT and type 2 diabetes. Although these studies demonstrate the beneficial effect of weight loss (WL) and AEX on glucose tolerance and insulin action, not much is known about the cellular and molecular mechanisms by which these nonpharmacologic treatments improve glucose utilization in high-risk obese older individuals.

This study seeks to determine the cellular mechanisms by which aerobic exercise and weight loss alter skeletal muscle insulin signaling to improve insulin action in older glucose intolerant individuals. A second purpose is to determine whether certain genes (hereditary information) affect the way the body utilizes glucose in response to exercise and weight loss. In addition, adipose tissue is increasingly recognized as more than an inert depot serving not only to accept and store excess energy in the form of triglycerides, but also to secrete hormones and adipokines that have substantial effects on lipid and glucose metabolism. Furthermore, there are depot differences in metabolic function, as well as adipokine content. However, the physiology both underlying and consequential to these observations remains unknown. Thus, a third aim is to examine the effects of obesity on regional adipokine secretion and expression, and the relationship of adipokines to insulin resistance and the metabolic syndrome.
PURPOSE:To obtain a new antibiotic substance MBA 028-24B, capable of exhibiting powerful growth inhibition to Gram-positive bacteria and molds and useful as an antimicrobial agent by culturing an actinomyces of the genus Streptomyces and collecting a product from the resultant culture. CONSTITUTION:An actinomyces [e.g. Streptomyces.hygroscopicus A1491 (FERM P-11864)] belonging to the genus Streptomyces is cultured to separate microbial cells from the culture solution by filtration and acetone is added to extract the culture solution. The extracted solution is then passed through an adsorbent resin column, adsorbed, eluted with methanol and purified by reverse phase partition chromatography to afford the objective new antibiotic substance having the following properties. Colorless powder. Specific rotatory power [alpha]<25>D=+53 deg. (c=1.0, methanol). Melting point; slowly colored and decomposed from 130 deg.C. Soluble in methanol, hydrous acetone and hydrous tetrahydrofuran and sparingly soluble or insoluble in ethanol. Positive to the Dragendorff reagent, phosphomolybdic acid and 10% sulfuric aid and negative to ninhydrin, Ehrlich reagent and ferric chloride.
OBJECTIVE: To compare the clinical effects of cortical bone trajectory screws and traditional pedicle screws in posterior lumbar fusion.
METHODS: A retrospective study was conducted to analyze lumbar degeneration patients who underwent surgical treatment at our hospital between January 2016 and January 2019. A total of 123 patients who met the inclusion criteria were enrolled. The subjects were divided into two groups according to their surgical procedures and the members of the two groups were matched by age, sex, and the number of fusion segments. There were 63 patients in the traditional pedicle screws (PS) group and 60 in the cortical bone trajectory screws (CBTS) group. The outcomes of the two groups were compared. The primary outcome measures were perioperative conditions, including operation duration, estimated intraoperative blood loss (EBL), and length-of-stay (LOS), visual analog scale (VAS) score, Oswestry Disability Index (ODI) score, and interbody fusion rate. The secondary outcome measures were the time to postoperative ambulation and the incidence of complications. VAS scores and ODI scores were assessed before operation, 1 week, 1 month, 3 months, and 12 months after operation, and at the final follow-up. The interbody fusion rate was assessed in 1 year and 2 years after the operation and at the final follow-up.
RESULTS: The CBTS group showed a reduction in operation duration ([142.8±13.1] min vs. [174.7±15.4] min, P<0.001), LOS ([9.5±1.5] d vs. [12.0±2.0] d, P<0.001), and EBL ([194.2±38.3] mL vs. [377.5±33.1] mL, P<0.001) in comparison with the PS group. The VAS score for back pain in the CBTS group was lower than that in the PS group at 1 week and 1 month after operation and the ODI score in the CBTS group was lower than that in the PS group at 1 month after operation, with the differences being statistically significant (P<0.05). At each postoperative time point, the VAS score for leg pain and the interbody fusion rate did not show significant difference between the two groups. The VAS score for back and leg pain and the ODI score at each time point after operation in both the CBTS group and the PS group were significantly lower than those before operation (P<0.05). No significant difference was found in the time to postoperative ambulation or the overall complication incidence between the two groups.
CONCLUSION: The CBTS technique could significantly shorten the operation duration and LOS, reduce EBL, and achieve the same effect as the PS technique does in terms of intervertebral fusion rate, pain relief, functional improvement, and complication incidence in patients undergoing posterior lumbar fusion.
There is no specific antidote for VIGAFYDE overdose. Standard measures to remove unabsorbed drug should be used, including elimination by emesis or gastric lavage. Supportive measures should be employed, including monitoring of vital signs and observation of the clinical status of the patient.

In an in vitro study, activated charcoal did not significantly adsorb vigabatrin.

The effectiveness of hemodialysis in the treatment of VIGAFYDE overdose is unknown. In isolated case reports in renal failure patients receiving therapeutic doses of vigabatrin, hemodialysis reduced vigabatrin plasma concentrations by 40% to 60%.
Rocatinlimab will be self-administered subcutaneously using a PFS. Participants will receive rocatinlimab for 52 weeks.
The present study investigates Internet-delivered CBT as a tertiary intervention. This is motivated by the fact that many pain patients relapse after rehabilitation and some may be in need of additional treatment. The persons who fulfills the inclusion criteria undergoes a structured telephone interview. The study is a experimental design with a treatment and an active control group measured before and after a treatment period. The control group were invited to participate in a moderated online discussion forum. Follow up data was collected six months after the treatment.
BACKGROUND: Apraxia has been identified in all clinical forms of frontotemporal lobar degeneration (FTLD). The characteristics of apraxia symptoms and their underlying cognitive/motor basis are not fully understood. This study investigated apraxia in pathological subtypes of FTLD.
METHODS: The study constituted a retrospective review of 115 pathologically confirmed cases of FTLD from a single cognitive neurology centre. Patients in whom apraxia had been documented as a notable clinical characteristic were identified. Apraxia features, demographic, cognitive, neurological, and imaging findings were recorded.
RESULTS: Eighteen patients were identified: 12 with FTLD-tau pathology (7 corticobasal degeneration (CBD), four Pick type and one progressive supranuclear palsy (PSP)) and six with FTLD-TDP pathology, all type A and four linked to progranulin gene mutations. Apraxia as a dominant presenting feature was typically associated with tau pathologies, whereas it emerged in the context of aphasia in TDP pathology. Apraxia typically predominated in one body part (face or limb) in tau but not TDP pathology. Relatively preserved activities in daily life were associated with TDP. Apraxia of speech was associated with tau pathology. Pick-type pathology was linked to symmetrical atrophy and late development of limb rigidity.
CONCLUSION: Apraxia in FTLD subtypes has variable characteristics. Apraxia associated with CBD pathology conformed to criteria for probable corticobasal syndrome (CBS), whereas apraxia with Pick-type pathology did not. Apraxia in patients with TDP-A pathology was interpreted as one manifestation of their generalised communication disorder. Apraxia in FTLD may have distinct cognitive and motor substrates that require prospective investigation.
Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery with blood cardioplegia for cardiac arrest (CABG) consists of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 minutes of reperfusion after induction of anesthesia before coronary artery bypass surgery. For myocardial molecular analyses, left ventricular biopsies are taken before induction of cardioplegic cardiac arrest and 5 to 10 Minutes after aortic unclamping during reperfusion of the myocardium. Blood samples are taken up to 72 hours postoperatively.
INTRODUCTION: Engaging patients living with or at risk of aortic dissection via the Aortic Dissection Collaborative, physician education in vascular genetics was identified as a research priority. We surveyed vascular surgeons to characterize practice patterns, motivations, and barriers regarding aortopathy genetic testing.
METHODS: An anonymous 27-question survey was distributed on social media platforms between November and December 2022. Domains included demographics, vascular genetic education, testing attitudes and utilization, and experience in treating patients with genetic vascular aortopathies. The analysis included summary statistics and unpaired t-test to compare responses by interest in incorporating testing and practice type.
RESULTS: A total of 171 vascular surgeons from 15 countries responded to the survey (23% trainees). Over half received vascular genetics education during training (59%), and most (86%) were interested in incorporating genetic testing into their practice. Academic surgeons were more likely to have cared for a patient with a known genetic aortopathy over the past year than surgeons in hospital-based and private practices (83% vs. 56% vs. 27%; P < 0.01), to have ever made a referral to a medical geneticist (78% vs. 51% vs. 9%; P < 0.01), and have access to genetic counselors or geneticists (66% vs. 46% vs. 0%; P < 0.01). Barriers to genetic testing were rated as more significant by surgeons in nonacademic practices, with top barriers being insurance coverage of testing, cost of genetic testing, and access to genetic counselors. Evidence-based professional society guidelines were the strongest rated motivating factor for testing incorporation among respondents.
CONCLUSIONS: Vascular surgeon attitudes are not major barriers to incorporating genetic testing for patients with aortopathies; however, practical challenges regarding genetic testing and counseling are barriers to implementation especially for vascular surgeons in nonacademic practices. Future efforts should focus on evidence-based society guidelines, continuing medical education to increase adoption, and facilitating access to genetic counseling.
Colloidal vol. replacement agent (I) comprises hydroxyethyl starch (HES) coupled stroma-free to haemoglobin (HGB). (I) can be used to replace blood and plasma losses of over 1.5 l. (in accidents, operations and illnesses), to pre-fill heart-lung machines in cardiac operations, as cardioplegia solns., perfusion in transplants, as a rheologically effective solns. with hyperonkotic activity and of low viscosity. The residue time of HGB in the circulation is increased by coupling with HES, and can be regulated by varying the type and degree of crosslinking and the m. wt. and degree of substn. of the HES. (I) can transport O2 and CO2. (I) does not transmit hepatitis or other diseases, is independent of blood group, can be prepd. in large quantities and is storage stable.